[{"NetIncomeLoss_1_Q3_USD":-16902507.0,"AccruedLiabilitiesCurrent_0_Q3_USD":2660824.0,"InterestPaidNet_3_Q3_USD":2415.0,"IncomeTaxesPaid_3_Q3_USD":null,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-35382926.0,"Depreciation_3_Q3_USD":2929.0,"ProceedsFromSaleOfShortTermInvestments_3_Q3_USD":53380266.0,"AssetsCurrent_0_Q3_USD":125465492.0,"OperatingLeaseExpense_3_Q3_USD":124400.0,"AccruedVacationCurrent_0_Q3_USD":312900.0,"ContractualObligationDueInNextTwelveMonths_0_Q3_USD":41400.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":6784690.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q3_USD":105875.0,"CommonStockSharesIssued_0_Q3_shares":16189258.0,"UnrealizedLossOnSecurities_3_Q3_USD":290973.0,"Assets_0_Q3_USD":125599441.0,"ShareBasedCompensation_3_Q3_USD":17586533.0,"ContractualObligation_0_Q3_USD":41400.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.001,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":19816597.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":16044670.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":15371118.0,"GeneralAndAdministrativeExpense_3_Q3_USD":18846299.0,"ClassOfWarrantOrRightOutstanding_0_Q3_shares":52268.0,"ResearchAndDevelopmentExpense_3_Q3_USD":21068923.0,"ResearchAndDevelopmentExpense_1_Q3_USD":11237186.0,"IncreaseDecreaseInPrepaidExpense_3_Q3_USD":1825336.0,"PrepaidExpenseCurrent_0_Q3_USD":2249199.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":1835888.0,"CommonStockValue_0_Q3_USD":16189.0,"WarrantsAndRightsOutstanding_0_Q3_USD":437100.0,"PrepaidExpenseCurrentAndNoncurrent_0_Q3_USD":2249200.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":27529174.0,"CashCashEquivalentsAndShortTermInvestments_0_Q3_USD":123100000.0,"OtherPrepaidExpenseCurrent_0_Q3_USD":25300.0,"AccruedLiabilitiesAndOtherLiabilities_0_Q3_USD":2660800.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":205970.0,"AccruedBonusesCurrentAndNoncurrent_0_Q3_USD":952300.0,"OtherAssetsNoncurrent_0_Q3_USD":25000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":7544728.0,"ContractualObligationDueInSecondYear_0_Q3_USD":null,"PreferredStockSharesOutstanding_0_Q3_shares":null,"GeneralAndAdministrativeExpense_1_Q3_USD":5946396.0,"InvestmentIncomeInterestAndDividend_3_Q3_USD":1174957.0,"InvestmentIncomeInterestAndDividend_1_Q3_USD":363300.0,"NotesPayable_0_Q3_USD":0.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q3_USD":14600.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-20880039.0,"ProceedsFromWarrantExercises_3_Q3_USD":7186306.0,"ProceedsFromWarrantExercises_1_Q3_USD":1567030.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_3_Q3_USD":0.0,"LiabilitiesCurrent_0_Q3_USD":3389457.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3_Q3_USD":-28733791.0,"AccountsPayableCurrent_0_Q3_USD":728633.0,"NonoperatingIncomeExpense_3_Q3_USD":1220958.0,"NonoperatingIncomeExpense_1_Q3_USD":281075.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":636518.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":70400.0,"IncreaseDecreaseInOtherOperatingAssets_3_Q3_USD":null,"AdditionalPaidInCapital_0_Q3_USD":280746968.0,"CashEquivalentsAtCarryingValue_0_Q3_USD":7544728.0,"PrepaidInsurance_0_Q3_USD":839400.0,"PreferredStockSharesIssued_0_Q3_shares":null,"PropertyPlantAndEquipmentNet_0_Q3_USD":2081.0,"NetIncomeLoss_3_Q3_USD":-38694264.0,"IncreaseDecreaseInLeasingReceivables_3_Q3_USD":-54242.0,"CommonStockSharesOutstanding_0_Q3_shares":16189258.0,"ContractualObligationDueAfterFifthYear_0_Q3_USD":null,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_1_Q3_USD":5244658.0,"CommonStockSharesAuthorized_0_Q3_shares":50000000.0,"OperatingIncomeLoss_3_Q3_USD":-39915222.0,"OperatingIncomeLoss_1_Q3_USD":-17183582.0,"SettlementLiabilitiesCurrent_0_Q3_USD":null,"PreferredStockValue_0_Q3_USD":null,"LiabilitiesAndStockholdersEquity_0_Q3_USD":125599441.0,"ProceedsFromRepaymentsOfNotesPayable_3_Q3_USD":-110247.0,"PreferredStockSharesAuthorized_0_Q3_shares":200000000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":17586500.0,"ShortTermInvestments_0_Q3_USD":115593750.0,"PropertyPlantAndEquipmentGross_0_Q3_USD":16700.0,"OperatingExpenses_1_Q3_USD":17183582.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-2.52,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-1.05,"ProfitLoss_1_Q3_USD":-16902507.0,"StockholdersEquity_0_Q3_USD":122209984.0,"UnrealizedGainLossOnDerivatives_3_Q3_USD":290973.0,"LeaseIncentiveReceivableNoncurrent_0_Q3_USD":106868.0,"LeaseIncentiveReceivableCurrent_0_Q3_USD":77815.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-158553173.0,"OperatingExpenses_3_Q3_USD":39915222.0,"AccruedProfessionalFeesCurrent_0_Q3_USD":213600.0,"Ticker":"RLMD","CIK":"1553643","name":"RELMADA THERAPEUTICS, INC.","OfficialName":"Relmada Therapeutics Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"772606380.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201112"}]